We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

ONL Therapeutics Inc. is a classic case of a University of Michigan spinout. The Ann Arbor biotechnology startup netted the largest VC deal in the state in Q3, closing an oversubscribed $65 million ...

Johnson and Johnson revealed lower earnings ... While it was a rocky year for the pharmaceutical company (and a particularly rocky quarter), the mega-corporation has strategized ways to keep ...

Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care ...

Well-established pharmaceutical stocks include AbbVie, Eli Lilly, Johnson & Johnson, and Pfizer. Investors should consider long-term growth, dividend history, and product pipelines. Key findings ...

The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of condition which causes abnormal ...

Johnson & Johnson shares advanced Tuesday after the pharmaceutical and medical device company posted better third-quarter sales and adjusted profit than expected. Net income fell sharply due to ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected to ...

Key Takeaways For Johnson & Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE ...

Key Takeaways For Johnson & Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE ...